

Symposium Program on Dose Selection for Cancer Treatments: May 12, 2017

Speaker: Shivaani Kummar
Professor and Director, Phase I Clinical Research Program,
Division of Oncology, Stanford Cancer Institute, Stanford University

Title: *Determining dose in the era of targeted anticancer agents*

Abstract:

The shift from cytotoxic chemotherapy to molecularly targeted agents has resulted in rethinking the drug development paradigm. I will discuss early phase trial designs, role of pharmacokinetics and pharmacokinetics in determining dose, integration of laboratory endpoints and molecular profiling into early phase trials. Define Basket and umbrella trials and the challenges of assigning therapy based on genetic sequencing to patients with advanced refractory cancers.